Comparison of efficacy and safety of intracoronary sodium nitroprusside and intravenous adenosine for assessing fractional flow reserve

Catheterization and Cardiovascular Interventions

Volumn 81, Issue 3, 2013, Pages 540-544

  Rudzinski, Wojciech ^a   Waller, Alfonso H ^a   Rusovici, Arthur ^a   Dehnee, Abed ^a   Nasur, Ali ^a   Benz, Michael ^a   Sanchez, Salvador ^a   Klapholz, Marc ^a   Kaluski, Edo ^a  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

Author keywords

adenosine; coronary artery disease; fractional flow reserve; hyperemia; sodium nitroprusside

Indexed keywords

ADENOSINE; GLYCERYL TRINITRATE; NITROPRUSSIDE SODIUM;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; CARDIOMYOPATHY; CORONARY ARTERY OBSTRUCTION; DIASTOLIC BLOOD PRESSURE; DRUG ACTIVITY; DRUG ADMINISTRATION ROUTE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; EXERCISE TEST; FEMALE; FLUSHING; FRACTIONAL FLOW RESERVE; HEART BLOCK; HEMODYNAMICS; HUMAN; HYPEREMIA; HYPOTENSION; INTRACORONARY DRUG ADMINISTRATION; LEFT VENTRICULAR SYSTOLIC DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; SIDE EFFECT; SINGLE DRUG DOSE; SINUS RHYTHM; STABLE ANGINA PECTORIS; SYSTOLIC BLOOD PRESSURE; THERAPY EFFECT; TREATMENT RESPONSE; UNSTABLE ANGINA PECTORIS;

ADENOSINE; CORONARY CIRCULATION; CORONARY STENOSIS; CORONARY VESSELS; FEMALE; FOLLOW-UP STUDIES; FRACTIONAL FLOW RESERVE, MYOCARDIAL; HUMANS; HYPEREMIA; INFUSIONS, INTRAVENOUS; INJECTIONS, INTRA-ARTERIAL; MALE; MIDDLE AGED; NITROPRUSSIDE; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; VASODILATION; VASODILATOR AGENTS;

EID: 84874029500     PISSN: 15221946     EISSN: 1522726X     Source Type: Journal    
DOI: 10.1002/ccd.24652     Document Type: Article

References (17)

1. Pijls NH, De Bruyne B, Peels K, Van Der Voort PH, Bonnier HJ, Bartunek J, Koolen JJ,. Measurement of fractional flow reserve to assess the functional severity of coronary artery stenoses. N Engl J Med 1996; 334: 1703-1708.
2. Tonino PA, De Bruyne B, Pijls NH, Siebert U, Ikeno F, Veer M, Klauss V, Manoharan, G, Engstrom T, Oldroyd KG, Ver Lee PN, MacCarthy PA, Fearon WF,. Fractional flow reserve versus angiography for guiding percutaneous coronary intervention. N Engl J Med 2009; 360: 213-224.
3. Pijls NH, van Son JA, Kirkeeide RL, De Bruyne B, Gould KL,. Experimental basis of determining maximum coronary, myocardial, and collateral blood flow by pressure measurements for assessing functional stenosis severity before and after percutaneous transluminal coronary angioplasty. Circulation 1993; 87: 1354-1367.
4. De Bruyne B, Pijls NH, Barbato E, Bartunek J, Bech JW, Wijns W, Heyndrickx GR,. Intracoronary and intravenous adenosine 5′-triphosphate, adenosine, papaverine, and contrast medium to assess fractional flow reserve in humans. Circulation 2003; 107: 1877-1883.
5. Pijls NH,. Optimum guidance of complex PCI by coronary pressure measurement. Heart 2004; 90: 1085-1093.
6. Wilson RF, Wyche K, Christensen BV, Zimmer S, Laxson DD,. Effects of adenosine on human coronary arterial circulation. Circulation 1990; 82: 1595-1606.
7. McGeoch RJ, Oldroyd KG,. Pharmacological options for inducing maximal hyperaemia during studies of coronary physiology. Catheter Cardiovasc Interv 2008; 71: 198-204.
8. De Luca G, Venegoni L, Iorio S, Giuliani L, Marino P,. Effects of increasing doses of intracoronary adenosine on the assessment of fractional flow reserve. JACC Cardiovasc Interv 2011; 4: 1079-1084.
9. Jeremias A, Whitbourn RJ, Filardo SD, Fitzgerald PJ, Cohen DJ, Tuzcu EM, Anderson WD, Abizaid AA, Mintz GS, Yeung AC, Kern MJ, Yock PG,. Adequacy of intracoronary versus intravenous adenosine-induced maximal coronary hyperemia for fractional flow reserve measurements. Am Heart J 2000; 140: 651-657.
10. Kern MJ, Deligonul U, Tatineni S, Serota H, Aguirre F, Hilton TC,. Intravenous adenosine: Continuous infusion and low dose bolus administration for determination of coronary vasodilator reserve in patients with and without coronary artery disease. J Am Coll Cardiol 1991; 18: 718-729.
11. Nair PK, Marroquin OC, Mulukutla SR, Khandhar S, Gulati V, Schindler JT, Lee JS,. Clinical utility of regadenoson for assessing fractional flow reserve. JACC Cardiovasc Interv 2011; 4: 1085-1092.
12. Cerqueira MD, Verani MS, Schwaiger M, Heo J, Iskandrian AS,. Safety profile of adenosine stress perfusion imaging: Results from the Adenoscan Multicenter Trial Registry. J Am Coll Cardiol 1994; 23: 384-389.
13. Bokhari S, Ficaro EP, McCallister BD Jr,. Adenosine stress protocols for myocardial perfusion imaging. J Nucl Cardiol 2007; 14: 415-416.
14. Cohn JN, Burke LP,. Nitroprusside. Ann Intern Med 1979; 91: 752-757.
15. Page IH, Corcoran AC, Dustan HP, Koppanyi T,. Cardiovascular actions of sodium nitroprusside in animals and hypertensive patients. Circulation 1955; 11: 188-198.
16. Hillegass WB, Dean NA, Liao L, Rhinehart RG, Myers PR,. Treatment of no-reflow and impaired flow with the nitric oxide donor nitroprusside following percutaneous coronary interventions: initial human clinical experience. J Am Coll Cardiol 2001; 37: 1335-1343.
17. Parham WA, Bouhasin A, Ciaramita JP, Khoukaz S, Herrmann SC, Kern MJ,. Coronary hyperemic dose responses of intracoronary sodium nitroprusside. Circulation 2004; 109: 1236-1243.